Notice. FG Capital Advisors provides structuring, transaction review, and commercial support relating to letters of credit, standby letters of credit, and guarantees. We are not a bank, not a rating agency, and not a law firm. This page is commercial and educational in nature and is not a legal opinion or credit rating advice.
The Obvious Risks Of Accepting Unrated Bank Or NBFC Letters Of Credit And Guarantees
A letter of credit or guarantee is only as useful as the institution standing behind it. That sounds obvious, yet people keep accepting instruments from unrated banks, weak banks, obscure offshore entities, or NBFCs that do not carry the same market standing as a serious commercial bank. Then they act surprised when discounting fails, confirmation is unavailable, or a draw turns into a fight.
The instrument may look polished. The wording may sound bankable. None of that matters if the issuer is not trusted, cannot perform, or is not accepted by the market.
Main problem:
- You are not really taking bank risk
- You may be taking weak issuer risk
- You may be taking jurisdiction risk
- You may discover that nobody serious will touch the paper
Hard truth. An LC or guarantee from the wrong issuer can be worse than useless. It can cause you to ship goods, extend credit, or release performance security based on protection the market does not actually recognize as dependable.
Why The Issuer Matters More Than The Instrument Name
Market participants love labels. LC. SBLC. Demand guarantee. Bank guarantee. None of those labels solve the core question: who is on the hook if the instrument is called? If the issuer is unrated, thinly capitalized, hard to verify, outside normal correspondent networks, or already viewed with suspicion by the market, the instrument can become difficult to confirm, discount, assign, enforce, or even trust operationally.
In other words, you are not accepting a promise on paper. You are accepting the credit quality, liquidity, legal environment, and payment discipline of the issuer.
The Most Obvious Risks
Non-payment risk If the issuer is weak, undercapitalized, illiquid, or politically exposed, a clean draw may still turn into delay, dispute, or default.
No market acceptance Even if the instrument is technically valid, major banks, confirmers, and discounting houses may refuse to touch it.
Enforcement difficulty If the issuer sits in a weak legal or regulatory environment, enforcing payment may be expensive, slow, and ugly.
Correspondent banking risk If the issuer lacks credible correspondent relationships, operational payment routes may be weaker than the beneficiary assumed.
Discounting failure A beneficiary may expect to monetize or discount the paper later and then discover there is no serious appetite for it.
Reputation and fraud risk Obscure issuers and NBFC structures are often used in transactions that already smell wrong.
Why NBFC Paper Often Creates Confusion
A lot of people hear “financial institution” and assume that means “bank equivalent.” It does not. An NBFC may be legitimate in its own lane, but that does not mean its guarantee or credit instrument will be treated by the market the same way a bank-issued instrument would be. The issue is not whether an NBFC exists legally. The issue is whether the beneficiary, the confirming bank, the discounting party, the supplier, or the off-taker actually accepts that credit.
That gap is where deals break. One side thinks it has delivered security. The other side knows it has received paper that may not be fundable or enforceable in practice.
Typical Commercial Mistakes
| Mistake | What Goes Wrong |
|---|---|
| Accepting the instrument at face value | The beneficiary checks wording but not the actual quality and acceptance of the issuer. |
| Assuming unrated means “hidden gem” | More often it means the market has less transparency and less confidence. |
| Assuming discounting will be easy later | Serious funders often screen the issuer before they even care about the rest of the file. |
| Treating an NBFC guarantee like a bank LC | The counterparty later discovers the paper is not equivalent in market acceptance or execution value. |
| Ignoring jurisdiction and enforceability | A “good” instrument can become a bad recovery story if the issuer sits in a difficult legal environment. |
What Beneficiaries Should Check First
Issuer quality Is the issuer known, supervised, credible, and accepted in the relevant market?
Real market acceptance Will reputable banks confirm it, take assignment risk, or consider discounting it?
Jurisdiction and enforceability Where is the issuer based, and what happens if payment is contested?
Operational route Is there a credible payment path, correspondent support, and standard banking workflow behind the paper?
Instrument purpose Is the instrument supporting a real commercial obligation, or is it being used to dress up a weak deal?
Beneficiary outcome If you had to draw tomorrow, would you genuinely trust the issuer to perform?
When A Weak Instrument Damages The Underlying Deal
This is the part people underestimate. A weak LC or guarantee does not just create credit risk. It can damage the commercial relationship. Suppliers may refuse to ship. Buyers may lose confidence. Funders may step back from the rest of the structure. The transaction starts looking amateurish, even if the underlying business was real.
In trade and project settings, credibility matters. Once the paper looks dubious, the whole file starts to smell off.
Where We Fit
We help clients review whether a proposed LC, SBLC, or guarantee is commercially usable, whether the issuer risk is acceptable, whether market acceptance is likely, and whether the instrument is being misused as fake comfort in a weak transaction. That matters because by the time the beneficiary learns the paper is weak, the commercial damage is often already done.
The right question is not whether the instrument looks formal. The right question is whether a serious market participant would actually trust the issuer standing behind it.
Disclosure. This page is for informational and commercial purposes only and does not constitute legal, tax, regulatory, rating, underwriting, or investment advice. Any acceptance, rejection, discounting, confirmation, or financing outcome remains subject to provider appetite, diligence, documentation, and definitive agreements.
